Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Short-term Investments (2019 - 2025)

IDEAYA Biosciences (IDYA) has disclosed Short-term Investments for 7 consecutive years, with $526.6 million as the latest value for Q4 2025.

  • Quarterly Short-term Investments fell 11.04% to $526.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $526.6 million through Dec 2025, down 11.04% year-over-year, with the annual reading at $526.6 million for FY2025, 11.04% down from the prior year.
  • Short-term Investments hit $526.6 million in Q4 2025 for IDEAYA Biosciences, up from $488.0 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $591.9 million in Q4 2024 to a low of $154.7 million in Q4 2021.
  • Historically, Short-term Investments has averaged $367.9 million across 5 years, with a median of $342.5 million in 2023.
  • Biggest YoY gain for Short-term Investments was 703.41% in 2021; the steepest drop was 26.86% in 2021.
  • Year by year, Short-term Investments stood at $154.7 million in 2021, then surged by 91.44% to $296.2 million in 2022, then rose by 24.27% to $368.1 million in 2023, then surged by 60.81% to $591.9 million in 2024, then decreased by 11.04% to $526.6 million in 2025.
  • Business Quant data shows Short-term Investments for IDYA at $526.6 million in Q4 2025, $488.0 million in Q3 2025, and $555.1 million in Q2 2025.